Carbimazole D3 is a synthetic medication which is used to treat hyperthyroidism, a condition in which the thyroid gland produces an excess of thyroid hormone. The drug works by inhibiting the production of thyroid hormone in the thyroid gland. Carbimazole D3 is a derivative of the drug Methimazole, which is also used to treat hyperthyroidism, but Carbimazole D3 is deuterated (contains a heavier isotope of hydrogen) which makes it useful in pharmacokinetic studies.
Carbimazole D3 is usually administered orally in the form of tablets. The dosage of Carbimazole D3 is determined by the severity of the patient's hyperthyroidism and their response to the drug. The drug is usually taken for several months, until the patient's thyroid hormone levels return to normal. Side effects of Carbimazole D3 may include nausea, vomiting, headache, and rash. In rare cases, the drug may cause more serious side effects such as liver damage or agranulocytosis (a decrease in white blood cell count).
Carbimazole D3 is a prodrug, which means that it is metabolized in the body to its active form, Methimazole. Methimazole works by inhibiting the enzyme thyroperoxidase, which is necessary for the production of thyroid hormone. Carbimazole D3 is a deuterated form of Methimazole, which means that it contains a heavier isotope of hydrogen. This makes it useful in pharmacokinetic studies, which are studies that examine how drugs are metabolized and excreted by the body. By using Carbimazole D3 instead of Methimazole, researchers can track the drug's metabolism more accurately.